ETIDIOH - NEW

  Antiviral Res XU M, Zhang Z, Sun Y, Mai H, et al IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility. Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082. PubMed           Abstract available CHUTIWITOONCHAI N, Akkarawongsapat R, Chantawarin S, Jiarpinitnun C, et al Antiviral effect of pinostrobin, a bioactive constituent of Boesenbergia rotunda, against porcine epidemic diarrhea virus. Antiviral Res. 2025;234:106073. PubMed           Abstract available BMJ AGIUS RM Healthcare workers should get covid-19 vaccinations. BMJ. 2025;388:r89. PubMed          Graefes Arch Clin Exp Ophthalmol KIM W, Park CM, Choi YJ, Kim DH, et al Recent trends and outcomes in immediate and delayed sequential bilateral cataract surgeries: a nationwide cohort study in South Korea. Graefes Arch Clin Exp ...

  Ann Intern Med VALE CL, Godolphin PJ, Fisher DJ, Higgins JPT, et al Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis. Ann Intern Med. 2024 Dec 24. doi: 10.7326/ANNALS-24-00800. PubMed           Abstract available Antiviral Res GAO M, Zhang Z, Yao G, Zhang L, et al Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents. Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060. PubMed           Abstract available MERCURI FA, Anderson GP, Miller BE, Demaison C, et al Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections. Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063. PubMed           Abstr...

Abstract As new SARS-CoV-2 variants continue to emerge , it is important to evaluate the potency of antiviral drugs to support their continued use. Remdesivir (RDV; VEKLURY®) an approved antiviral treatment for COVID-19, and obeldesivir (ODV) are inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase Nsp12. Here we show these two compounds retain antiviral activity against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, JN.1.7, JN.1.18, KP.2, KP.3, LB.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF when compared with reference strains. Genomic analysis identified 29 Nsp12 polymorphisms in these and previous Omicron variants. Phenotypic analysis of these polymorphisms confirmed no impact on the antiviral activity of RDV or ODV and suggests Omicron variants containing these Nsp12 polymorphisms remain susceptible to both compounds. These data support the continued use of RDV in the context of circulating SARS-CoV-2 vari...

Abstract The repeated spill-over of Influenza A virus H5N1 clade 2.3.4.4b from cattle to humans highlights the risk of a human H5N1 pandemic . Given the impact of pre-existing immunity on the course and severity of viral infections , we assessed in detail the humoral immunity against the H5N1 A/Texas/37/2024 isolate in H5N1-naive individuals . To this end, we performed complementary binding and neutralization assays on 66 subjects and ranked activities among a panel of 76 influenza A virus isolates . We detected low but distinct cross-neutralizing titers against A/Texas/37/2024 with a 3.9 to 15.6-fold reduction compared to selected H1N1 or H3N2 strains. Moreover, by cloning and evaluating 136 monoclonal antibodies from single memory B cells , we identified potent A/Texas/37/2024-neutralizing monoclonal antibodies in five out of six investigated individuals. These antibodies predominantly utilize VH1-69 gene segments, cross-neutralize H1, and compete with antibodies targeting the HA ste...